CaCO3
Place in Therapy
The available evidence indicates that other treatment options are more effective than calcium carbonate for the treatment of GERD. Any benefit seems to be purely from symptomatic relief. The role it has in therapy as a single-agent should be limited to the initial 1-2 weeks of symptoms to treat self-limiting conditions. If symptoms persist the patient should be referred to a physician for assessment and another agent started.
Calcium carbonate may have a role for mild GERD, or when symptoms present ≤ 3 times per week. It may also be used to treat breakthrough symptoms such as postprandial heartburn. In this role, intake of calcium carbonate may be useful in evaluating the efficacy of primary treatment.
References
1. Williams D, Schade R. Gastroesophageal Reflux Disease. Pharmacotherapy: A Pathophysiological Approach, 8th Edition. Chapter 29.
2. Fennerty M, Finke K, Kushner P et al. Short and Long-Term Management of Heatburn and Other Acid-Related Disorders: Development of An Algorithm For Primary Care Providers. The Journal of Family Practice (2009): 58(7); S1-212.
3. Pettit M. Treatment of Gastroesophageal Reflux Disease. Pharmacy World & Science (2005) 27: 432-435.
4. Hershcovici T and Fass R. Pharmacological Mangement of GERD: Where Does It Stand Now? Trends In Pharmacological Sciences (2001): 32(4); 258-264.
5. Earnest D, Robinson M, Rodriquez-Stanley S et al. Managing Heartburn At The ‘Base’ of The GERD ‘iceberg’: Effervescent Ranitidine 150mg B.D. Provides Faster and Better Heartburn Relief Than Antacids. Alimentary Pharmacology & Therapeutics (2000): 14(7); 911-918.
6. Rayburn W, Liles E, Christensen H, Robinson M. Anatacids vs. Antacids Plus Non-Prescription Ranitidine For Heartburn During Pregnancy. International Journal of Gynecology & Obstetrics (1999): 66; 35-37.